|Bid||3.5000 x 800|
|Ask||3.6600 x 1000|
|Day's Range||3.6300 - 3.9200|
|52 Week Range||3.6300 - 14.1700|
|Beta (5Y Monthly)||2.31|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 23, 2022 - Feb 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for CGENLearn more
New York, NY, based Investment company Edge Wealth Management LLC (Current Portfolio) buys SPDR Biotech ETF, Salesforce.com Inc, Invesco BulletShares 2024 Corporate Bond ETF, Invesco Senior Loan ETF, iShares J.P.
Compugen Ltd. (NASDAQ-GM: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the United States Patent and Trademark Office (USPTO) has granted Compugen a new patent covering method of use for COM701, Compugen's potential first-in-class therapeutic antibody targeting PVRIG, or back-up anti-PVRIG antibody, in triple combination with any anti-PD-1 and any anti-TIGIT antibody for the treatment of cancer.
Investment company Timothy Plan Israel Common Values Fund (Current Portfolio) buys Kornit Digital, Fattal Holdings (1998), Energean PLC, Rada Electronics Industries, Tremor International, sells Cognyte Software, Cognyte Software, Compugen, Electreon Wireless, NRX Pharmaceuticals Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Timothy Plan Israel Common Values Fund.